References
- Zisman DA, Schwarz M, Anstrom KJ, A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363(7):620–628
- Peacock AJ, Naeije R, Galie N, End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Eur Respir J 2009; 34(1):231–242.
- Anonymous. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166(1):111–117.
- Simonneau G, Rubin LJ, Galie N, Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149(8):521–530.
- Bestall JC, Paul EA, Garrod R, Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54(7):581–586.
- Parshall MB, Schwartzstein RM, Adams L, An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012; 185(4):435–452
- Casanova C, Cote C, Marin JM, Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. Chest 2008; 134(4):746–752.
- Pellegrino R, Viegi G, Brusasco V, Interpretative strategies for lung function tests. Eur Respir J 2005; 26(5):948–968.
- Miller MR, Crapo R, Hankinson J, General considerations for lung function testing. Eur Respir J 2005; 26(1):153–161.
- Lemaire F. Do all types of human research need ethics committee approval? Am J Respir Crit Care Med 2006; 174(4):363–364.
- Casanova C, Celli BR, Barria P, The 6-min walk distance in healthy subjects: reference standards from seven countries. Eur Respir J 2011; 37(1):150–156.
- Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1998; 158(5 Pt 1):1384–1387.
- Rabe KF, Hurd S, Anzueto A, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007; 176(6):532–555.
- Anonymous. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165(2):277–304.
- Meyer G, Planquette B, Sanchez O. Long-term outcome of pulmonary embolism. Curr Opin Hematol 2008; 15(5):499–503
- Sanchez O, Caumont-Prim A, Gillet-Juvin K, Activity-related dyspnea is not modified by psychological status in people with COPD, interstitial lung disease or obesity. Respir Physiol Neurobiol 2012;182(1):18–25.
- Smadja DM, Mauge L, Sanchez O, Distinct patterns of circulating endothelial cells in pulmonary hypertension. Eur Respir J 2011; 36(6):1284–1293.
- Sanchez O, Helley D, Couchon S, Perfusion defects after pulmonary embolism: risk factors and clinical significance. J Thromb Haemost 2010; 8(6):1248–1255.
- Burdon JG, Juniper EF, Killian KJ, The perception of breathlessness in asthma. Am Rev Respir Dis 1982; 126(5):825–828.
- Callens E, Graba S, Gillet-Juvin K, Measurement of dynamic hyperinflation after a 6-minute walk test in patients with COPD. Chest 2009; 136(6):1466–1472.
- Abidov A, Rozanski A, Hachamovitch R, Prognostic significance of dyspnea in patients referred for cardiac stress testing. N Engl J Med 2005; 353(18):1889–1898.